The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are ...

PHILADELPHIA, April 16, 2025--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainant flagged “a shocking error” in the prescribing information for the JAK inhibitor Omjjara. A person who ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré Syndrome, according to experts in the US ...

FDA Warnings and Recalls Abrysvo® and Arexvy®: RSV Vaccines In January, the FDA announced that prescribing information for Abrysvo (RSV vaccine) and Arexvy (RSV vaccine, adjuvanted) had been updated ...

The agency requested a similar study to evaluate GBS risk in adults ages 50 and older vaccinated with Arexvy. The FDA further determined that the benefits of vaccination with the two RSV vaccines ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

HealthDay News — The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) ...